AR and prostate carcinoma: CTCs isolated from patients with mCRPC have demonstrated features consistent with those of prostate cancer, including the expression of PSA, AMACR and prostate-specific gene abnormalities; these include androgen receptor copy number amplifications, phosphatase and tensin homolog deletions and TMPRSS2:ERG fusion products [11,12].